CEO of Newamsterdam Pharma Accumulates Shares Amid Quiet Insider Trades – Signals Optimism Despite Losses

Insider Activity at Newamsterdam Pharma: A Close‑Read of the CEO’s Trades

Recent Moves by CEO Davidson Michael H. On February 24‑26, 2026, the company’s Chief Executive Officer executed a series of buys and sells that netted a modest gain. The CEO purchased 64,708 shares on the 24th at no disclosed price (likely through an option exercise at €1.16392) and added another 58,253 shares on the 25th, boosting his holdings to 518,112 shares. He then sold 61,547 shares at an average of $36.13, 3,161 shares at $36.46, and 10,436 shares at $35.96 between the 24th and 25th, and finally offloaded 165,408 shares at $33.63 and 17,924 shares at $34.44 on the 26th. These transactions leave him with 174,144 shares after the 26th sale and an additional 285,715 shares transferred into a Grantor Retained Annuity Trust (GRAT), a move that is exempt from Section 16 reporting. The net effect of the trades is a slight increase in his overall stake, reflecting confidence in the company’s near‑term prospects.

Implications for Investors The CEO’s pattern of buying while the market sits near the 52‑week low ($14.06) and its current price ($36.01) suggests a bullish stance on Newamsterdam’s pipeline. The company’s negative P/E of –20.78 signals ongoing losses, yet the CEO’s continued accumulation—especially through option exercises—implies that the executive believes the valuation will rebound as the company progresses through late‑stage clinical trials. For investors, the CEO’s activity is a positive sign of alignment between management and shareholders, but the modest size of the trades and the relatively flat social‑media sentiment (0) mean that the moves should be viewed as incremental rather than a decisive endorsement.

A Profile of Davidson Michael H. Davidson’s insider history shows a mix of option exercises and share purchases, with a notable pattern of exercising options that were granted to replace earlier awards post‑business combination. In January 2026, he bought 81,000 shares and sold 11,582 shares, maintaining a stable stake of around 459,859 shares. His option activity—364,000 shares exercised on January 7—indicates a willingness to convert long‑term equity awards into cash or stock as opportunities arise. The recent transfer to a GRAT is a strategic tax move, allowing him to preserve wealth while avoiding insider‑trade reporting. Overall, Davidson appears to be a patient investor who balances short‑term liquidity needs with a long‑term commitment to the company’s growth trajectory.

Broader Insider Trends Other key executives—chief scientific officer Johannes Kastelein and chief accounting officer Louise Kooij—have also been active, selling shares in the $35–$36 range. This broader insider selling could signal short‑term profit taking, yet the CEO’s buying offsets these outflows, suggesting that senior management remains optimistic about Newamsterdam’s future. The company’s upcoming investor conferences in March 2026 may provide further clarity on pipeline milestones, which could influence both insider activity and market sentiment.

Bottom Line Davidson Michael H.’s recent trading activity reflects confidence in Newamsterdam Pharma’s clinical pipeline and an intent to maintain a sizable equity position despite ongoing losses. For shareholders, the CEO’s buying is a reassuring signal of management alignment, though the modest trade sizes and lack of dramatic market reaction suggest that investors should monitor forthcoming clinical data and conference presentations for any substantive shifts in valuation dynamics.